Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
Related Questions
What are your biggest takeaways from the MASH-TAG 2025 conference?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
How do you approach a patient who has incidentally found liver and renal cysts?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
How do you incorporate addiction medicine and counseling into your treatment plan for patients with alcohol associated liver disease?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
In what scenario do you continue surveillance of benign liver tumors, e.g., hepatocellular adenoma, in pregnant patients?
